Prevalence of FGIDs and Probiotics Study
Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology
Chulalongkorn University
512 participants
Mar 14, 2024
INTERVENTIONAL
Conditions
Summary
This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.
Eligibility
Inclusion Criteria5
- Healthy and term (GA 37-41 weeks) infants
- Appropriate weight for age
- APGAR score more than 8 at 10 minutes of life
- Normal physical examination
- Mothers have no previous probiotics use
Exclusion Criteria2
- not willing to anticipate in the study
- cannot come to follow-up until 1 year of age
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06309199